ccr7 (fitc) 150503  (R&D Systems)

Journal: Scientific Reports

Article Title: Immunomodulatory effect of IFN-γ licensed adipose-mesenchymal stromal cells in an in vitro model of inflammation generated by SARS-CoV-2 antigens

doi: 10.1038/s41598-024-75776-5

Figure Lengend Snippet: Assessment of activation markers and memory T-cells. (A-E) Expression of CD69, CD137, CD38, and CD25 on T-cells after the culture of PBMCs with NS antigens in iCM, and coculture or not with IFN-γ-licensed MSCs. Representative flow cytometry plots of T-cells positive for CD69, CD137, CD38, and CD25 are shown on the left. (F-J) Percentage of naive T-cells, TEM, TEMRA, and TCM after culture of PBMCs in RPMI medium, with NS antigens in iCM, and coculture with IFN-γ-licensed MSCs. Representative gating strategy and flow cytometry plots of CCR7 and CD45RA expression on T-cells are shown on the left. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Then, IFN-γ-licensed MSCs were added to the PBMCs exposed to NS antigens and iCM (10:1 ratio) and cocultured for 72 h. After this period, the PBMCs were collected and stained with the following-conjugated antibodies: CD3-PE (Invitrogen), CD197 (CCR7)-FITC (Invitrogen) and CD45RA-APC (Invitrogen).

Techniques: Activation Assay, Expressing, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity

doi: 10.1016/j.xcrm.2024.101628

Figure Lengend Snippet: Long-term resistance of normal T cells to CD5.CART cells is mediated by the loss of CD5 gene expression (A) Gating strategy (top). CD5 expression of T cells in patient #5 treated with CD5.CART cells that produced an abbreviated expansion (bottom). (B) CD3 + T cells in peripheral blood of patients with T cell lymphoma (TCL) or T cell acute lymphoblastic leukemia (T-ALL) treated with CD5.CART cells (NCT03081910). (C) CD5 expression of T cells in patient #7 (top), #8 (middle), and #9 (bottom) with durable CD5.CART cell persistence and achieved complete response. (D) CD5 mRNA expression of healthy T cells isolated from a lymph node biopsy at week 5 in patient #7 (left) and week 4 in patient #8 (right) normalized to respective donors’ T cells pre-lymphodepletion. (E) T cell phenotype of healthy T cells based on CCR7 and CD45RA expression of patient #7, #8, and #9. Naive (CCR7 + /CD45RA + ), central memory (CCR7 + /CD45RA − ), effector memory (CCR7 − /CD45RA − ), TEMRA (CCR7 − /CD45RA + ), and CD4/CD8 T cell distributions in healthy circulating T cells in patient #7, #8, and #9.

Article Snippet: Mouse anti-human CD197 (CCR7) FITC (clone 150503) , BD Biosciences , Cat#561271; RRID: AB_10561679.

Techniques: Expressing, Produced, Isolation

Journal: Cell Reports Medicine

Article Title: Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity

doi: 10.1016/j.xcrm.2024.101628

Figure Lengend Snippet:

Article Snippet: Mouse anti-human CD197 (CCR7) FITC (clone 150503) , BD Biosciences , Cat#561271; RRID: AB_10561679.

Techniques: Enzyme-linked Immunosorbent Assay, Antibody Labeling, Western Blot, Sequencing, CRISPR, Software